Key result
Imatinib partially rescues valve defects by inhibiting PDGF-B signaling driven by PROX1 deficiency.
Why the study?
Effective pharmacological treatments for cardiac valve disease are lacking, and whether the lymphatic and venous valve transcription factors PROX1 and FOXC2 regulate cardiac valve development and disease was unknown.
Does pharmacological inhibition of PDGF-B signaling with imatinib prevent myxomatous degeneration of heart valves in Prox1-deficient mice?
Does pharmacological inhibition of PDGF-B signaling with imatinib prevent myxomatous degeneration of heart valves in Prox1-deficient mice?
This basic science study identifies the PROX1-FOXC2-PDGF-B signaling axis as a critical regulator of heart valve integrity and suggests PDGF-B inhibition as a potential pharmacological strategy for myxomatous valve disease.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PDGF-B inhibition in myxomatous valve disease; prospective human studies needed before any clinical consideration.
BACKGROUND: Cardiac valve disease is observed in 2.5% of the general population and 10% of the elderly people. Effective pharmacological treatments are currently not available, and patients with severe cardiac valve disease require surgery. PROX1 (prospero-related homeobox transcription factor 1) and FOXC2 (Forkhead box C2 transcription factor) are transcription factors that are required for the development of lymphatic and venous valves. We found that PROX1 and FOXC2 are expressed in a subset of valvular endothelial cells (VECs) that are located on the downstream (fibrosa) side of cardiac valves. Whether PROX1 and FOXC2 regulate cardiac valve development and disease is not known. METHODS: We used histology, electron microscopy, and echocardiography to investigate the structure and functioning of heart valves from Prox1 ΔVEC mice in which Prox1 was conditionally deleted from VECs. Isolated valve endothelial cells and valve interstitial cells were used to identify the molecular mechanisms in vitro, which were tested in vivo by RNAScope, additional mouse models, and pharmacological approaches. The significance of our findings was tested by evaluation of human samples of mitral valve prolapse and aortic valve insufficiency. RESULTS: Histological analysis revealed that the aortic and mitral valves of Prox1 ΔVEC mice become progressively thick and myxomatous. Echocardiography revealed that the aortic valves of Prox1 ΔVEC mice are stenotic . FOXC2 was downregulated and PDGF-B (platelet-derived growth factor-B) was upregulated in the VECs of Prox1 ΔVEC mice. Conditional knockdown of FOXC2 and conditional overexpression of PDGF-B in VECs recapitulated the phenotype of Prox1 ΔVEC mice. PDGF-B was also increased in mice lacking FOXC2 and in human mitral valve prolapse and insufficient aortic valve samples. Pharmacological inhibition of PDGF-B signaling with imatinib partially ameliorated the valve defects of Prox1 ΔVEC mice. CONCLUSIONS: PROX1 antagonizes PDGF-B signaling partially via FOXC2 to maintain the extracellular matrix composition and prevent myxomatous degeneration of cardiac valves.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2023) studied Myxomatous degeneration of heart valves. Imatinib vs. Vehicle was evaluated on Aortic valve thickness and function (stenosis) by echocardiography and histology. PROX1 antagonizes PDGF-B signaling to prevent myxomatous degeneration of cardiac valves, and pharmacological inhibition of this pathway with imatinib partially rescued valve defects in Prox1 ΔVEC mice.
Synapse has enriched 10 related papers. Consider them for comparative context: